Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lantern Pharma Inc
(NQ:
LTRN
)
4.650
+0.430 (+10.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lantern Pharma Inc
< Previous
1
2
3
4
5
6
Next >
Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting
March 15, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET
March 13, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank
March 13, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors
March 09, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.
March 08, 2023
From
Lantern Pharma
Via
Business Wire
Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers
March 06, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials
March 02, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352
February 27, 2023
From
Lantern Pharma Inc.
Via
Business Wire
7 AI Penny Stocks That Could Skyrocket in 2023
February 21, 2023
AI penny stocks represent great potential and high returns, given the fact this technology is only beginning to pervade society.
Via
InvestorPlace
Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates
February 15, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023
January 17, 2023
From
Lantern Pharma Inc.
Via
Business Wire
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma
January 05, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting
December 15, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)
December 13, 2022
From
Lantern Pharma Inc.
Via
Business Wire
BioMedNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) to Present at RHK Capital Disruptive Growth Conference
December 02, 2022
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting
November 22, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights
November 07, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Earnings Preview: Lantern Pharma
November 04, 2022
Lantern Pharma (NASDAQ:LTRN) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Lantern Pharma...
Via
Benzinga
Lantern Pharma Management to Present at Upcoming Investor Conferences in Q4
November 02, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4:30 p.m. ET
October 31, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma to Present New Preclinical Data at Three Upcoming Scientific Conferences
October 25, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Upgrades
Via
Benzinga
Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET
October 21, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
October 28, 2022
During Friday, 125 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
October 27, 2022
On Thursday, 111 stocks hit new 52-week lows.
Via
Benzinga
Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300
October 20, 2022
From
Lantern Pharma Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 12, 2022
Gainers Adamis Pharmaceuticals (NASDAQ:ADMP) shares moved upwards by 28.1% to $0.19 during Wednesday's pre-market session. The market value of their outstanding shares is at $28.1 million.
Via
Benzinga
Lantern Pharma to Present at The MicroCap Rodeo Presents The Windy City Roundup 2022 on Wednesday, October 12 at 11:00 a.m. ET
October 11, 2022
Via
ACCESSWIRE
Lantern Pharma to Present at Upcoming Investor Conferences
October 05, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting
September 23, 2022
From
Lantern Pharma Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.